Analytical Data
-
Gene name
inaX
- Application
-
Alternative Names
inaX；Interferon alpha-7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01567
-
Expression Region
1-189aa
-
AA Sequence
MARSFSLLMVVLVLSYKSICSLGCDLPQTHSLRNRRALILLAQMGRISPFSCLKDRHEFRFPEEEFDGHQFQKTQAISVLHEMIQQTFNLFSTEDSSAAWEQSLLEKFSTELYQQLNDLEACVIQEVGVEETPLMNEDFILAVRKYFQRITLYLMEKKYSPCAWEVVRAEIMRSFSFSTNLKKGLRRKD
-
Molecular Weight
22.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of inaX recombinant proteins is deeply rooted in the quest to understand the molecular mechanisms underpinning bacterial communication and virulence. InaX, a protein associated with certain pathogenic strains, plays a significant role in host-pathogen interactions, influencing the ability of bacteria to colonize and evade immune responses. Researchers are particularly interested in analyzing the structure and function of inaX to identify potential therapeutic targets and develop innovative strategies for combating bacterial infections. The increasing prevalence of antibiotic resistance accentuates the urgency of this research, as traditional treatment methods become less effective. By utilizing recombinant DNA technology, scientists can produce and characterize inaX in controlled laboratory conditions, allowing for detailed investigations into its biological properties and interactions with host cells. Understanding the precise role of inaX not only provides insights into bacterial pathogenesis but also has broader implications for the development of vaccines and novel antimicrobial agents. This protein's study is thus positioned at the intersection of microbiology, immunology, and biochemistry, aiming to unveil critical aspects of bacterial life cycles and host responses.
